An Idaho representative seeks to shield execution team members, and grant greater power to the state prison director over ...
Watch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation ...
Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.
PM Modi blasted the prior 'AAPda' regime for a decade of stalled progress—delaying Metro Phase-IV for politics, snubbing ...
Becton, Dickinson and Company ( BDX) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:30 AM EDT Good morning. Thanks very much for joining us. Very pleased today to have with us Tom ...
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...
Intraocular inflammation following high dose aflibercept may be more common in practice than phase 3 trials found.
CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority ...
A Main Line Today editor shares what happened when she had a seat and took the leap into IV therapy not once, but twice.
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1066.06, with a ...
Westgold Resources Limited (Westgold or the Company) is pleased to announce that its Board has approved the Final Investment Decision (FID) to expand the Higginsville Processing Hub from 1.6Mtpa to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results